MX421763B - Metodos y composiciones que comprenden proteina d tensoactiva (sp-d) - Google Patents

Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)

Info

Publication number
MX421763B
MX421763B MX2020010030A MX2020010030A MX421763B MX 421763 B MX421763 B MX 421763B MX 2020010030 A MX2020010030 A MX 2020010030A MX 2020010030 A MX2020010030 A MX 2020010030A MX 421763 B MX421763 B MX 421763B
Authority
MX
Mexico
Prior art keywords
protein
surfactin
compositions
methods
rhsp
Prior art date
Application number
MX2020010030A
Other languages
English (en)
Other versions
MX2020010030A (es
Inventor
Derrick S Katayama
Giovanni M Pauletti
Jan Susan Rosenbaum
Mark Cornell Manning
Ryan Holcomb
Shawn Grant
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of MX2020010030A publication Critical patent/MX2020010030A/es
Publication of MX421763B publication Critical patent/MX421763B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende proteína D tensoactiva humana recombinante (rhSP-D) o un fragmento activo de la misma, un amortiguador de histidina, una azúcar y una sal de calcio.
MX2020010030A 2018-03-29 2019-03-27 Metodos y composiciones que comprenden proteina d tensoactiva (sp-d) MX421763B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650142P 2018-03-29 2018-03-29
PCT/US2019/024305 WO2019191247A1 (en) 2018-03-29 2019-03-27 Methods and compositions comprising surfactant protein d (sp-d)

Publications (2)

Publication Number Publication Date
MX2020010030A MX2020010030A (es) 2021-01-15
MX421763B true MX421763B (es) 2025-03-14

Family

ID=68060728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010030A MX421763B (es) 2018-03-29 2019-03-27 Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)

Country Status (12)

Country Link
US (1) US12491234B2 (es)
EP (1) EP3774875B1 (es)
JP (1) JP7797098B2 (es)
KR (1) KR102917619B1 (es)
CN (1) CN112119088A (es)
AU (1) AU2019243707B2 (es)
BR (1) BR112020019861A2 (es)
CA (1) CA3095043A1 (es)
IL (1) IL277468B2 (es)
MX (1) MX421763B (es)
RU (1) RU2020131642A (es)
WO (1) WO2019191247A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773675B1 (en) 2018-03-29 2024-12-04 Airway Therapeutics, Inc. Systems and methods for characterizing surfactant protein d (sp-d) oligomers
AU2021258178A1 (en) * 2020-04-22 2022-11-17 Airway Therapeutics, Inc. Use of surfactant protein D to treat viral infections
JPWO2023145916A1 (es) * 2022-01-31 2023-08-03
WO2023145915A1 (ja) * 2022-01-31 2023-08-03 積水メディカル株式会社 肺サーファクタントプロテインの免疫測定方法及び免疫測定試薬
AU2024373079A1 (en) 2023-11-02 2025-10-23 Airway Therapeutics, Inc. Methods for treating premature newborn infants by administration of recombinant human surfactant protein d (rhsp-d)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838428B2 (en) 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US8933032B2 (en) * 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
JP3573330B2 (ja) * 1999-07-22 2004-10-06 ヤマサ醤油株式会社 安定化された抗原含有水溶液
JP3418827B2 (ja) 2000-03-15 2003-06-23 ミネベア株式会社 Ｍｎ−Ｚｎフェライトおよびその製造方法
EP1440083B1 (en) 2001-10-25 2013-01-02 Medical Research Council Molecules
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
MX336323B (es) 2010-04-15 2016-01-15 Genentech Inc Anticuerpos de anti-poliubiquitina y metodos de uso.
ES2738914T3 (es) 2011-01-05 2020-01-27 Prenatal Int Gmbh Composición acuosa hipotónica con bajo contenido de cloruro, con o sin fosfolípidos
US20120220531A1 (en) * 2011-02-04 2012-08-30 Cincinnati Children's Hospital Medical Center Surfactant protein d for the treatment of disorders associated with lung injury
WO2013068593A1 (en) 2011-11-11 2013-05-16 Philip Morris Products S.A. Influenza virus -like particles (vlps) comprising hemagglutinin produced nicotiana tabacum
MX2015003007A (es) 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
JP2020534814A (ja) 2017-09-06 2020-12-03 エアウェイ・セラピューティクス・インコーポレイテッド サーファクタントタンパク質ｄ（ｓｐ−ｄ）を調製するための方法、組成物、及び細胞
KR102831403B1 (ko) 2017-09-06 2025-07-09 에어웨이 테라퓨틱스, 아이엔씨. 계면활성제 단백질 d (sp-d)를 제조하는 방법 및 조성물
EP3773675B1 (en) 2018-03-29 2024-12-04 Airway Therapeutics, Inc. Systems and methods for characterizing surfactant protein d (sp-d) oligomers

Also Published As

Publication number Publication date
AU2019243707A1 (en) 2020-10-15
IL277468B1 (en) 2024-05-01
EP3774875C0 (en) 2026-03-18
EP3774875A1 (en) 2021-02-17
US20210121536A1 (en) 2021-04-29
JP2021519757A (ja) 2021-08-12
IL277468A (en) 2020-11-30
BR112020019861A2 (pt) 2021-01-05
CA3095043A1 (en) 2019-10-03
KR102917619B1 (ko) 2026-01-27
IL277468B2 (en) 2024-09-01
AU2019243707B2 (en) 2023-12-07
CN112119088A (zh) 2020-12-22
EP3774875A4 (en) 2022-01-12
EP3774875B1 (en) 2026-03-18
JP7797098B2 (ja) 2026-01-13
MX2020010030A (es) 2021-01-15
US12491234B2 (en) 2025-12-09
RU2020131642A (ru) 2022-04-29
KR20210007961A (ko) 2021-01-20
WO2019191247A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
MX2022006758A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
BR112016026811A2 (pt) formulação de anticorpo
PE20220375A1 (es) Proteinas quimericas insecticidas novedosas toxicas o inhibidoras de plagas de lepidopteros
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
EA201792245A1 (ru) Биоконъюгаты и их применения
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX385972B (es) Partículas y composiciones de nicotina.
BR112019023846A2 (pt) composição farmacêutica de anticorpo de pd-l1 e uso da mesma
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
CL2020001307A1 (es) Formulación.
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
MX2020010030A (es) Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
EA202092335A1 (ru) Композиции на основе эренумаба и пути их применения
MX2019002248A (es) Proteina de union al factor h modificada.
NI201900072A (es) UNA COMPOSICION FARMACEUTICA ACUOSA DE ANTICUERPO MONOCLONAL ANTICUERPO MONOCLONAL ANTI-TNFalfa RECOMBINANTE
PE20151999A1 (es) Composiciones nutricionales que contienen un componente peptidico y usos del mismo